Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

Tabernero J.; van Geel R.; Bendell J. C.; Spreafico A.; Schuler M.; Yoshino T.; Delord J. P.; Yamada Y.; Lolkema M. P.; Fans J. E.; Eskens F. A. L. M.; Sharma S.; Yaeger R.; Lenz H. J.; Wainberg Z.; Avsar E.; Chatterjee A.; Jaeger S.; Demuth T.; Schellens J. H. M.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

【24h】

Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

机译：晚期BRAF突变性结直肠癌患者中选择性BRAFV600抑制剂恩可拉非尼（LGX818）联合西妥昔单抗联合或不联合α-特异性PI3K抑制剂alpelisib（BYL719）的第一阶段研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Tabernero J.; van Geel R.; Bendell J. C.; Spreafico A.; Schuler M.; Yoshino T.; Delord J. P.; Yamada Y.; Lolkema M. P.; Fans J. E.; Eskens F. A. L. M.; Sharma S.; Yaeger R.; Lenz H. J.; Wainberg Z.; Avsar E.; Chatterjee A.; Jaeger S.; Demuth T.; Schellens J. H. M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer [J] . Tabernero J., van Geel R., Bendell J. C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：晚期BRAF突变性结直肠癌患者中选择性BRAFV600抑制剂恩可拉非尼（LGX818）联合西妥昔单抗联合或不联合α-特异性PI3K抑制剂alpelisib（BYL719）的第一阶段研究
2. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results [J] . Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, Journal of Translational Medicine . 2014,第SUPPLEMENTa1期

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的Ib / II期，开放标签，剂量递增研究，用于BRAF V600依赖性晚期实体瘤患者：初步结果
3. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study [J] . Van Cutsem Eric, Huijberts Sanne, Grothey Axel, Journal of Clinical Oncology . 2019,第17期

机译：Binimetinib，Encorafenib和Cetuximab Triplet患者对BRAF V600E - 突变转移结直肠癌的患者：III阶段信标直肠癌研究的安全引入结果
4. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer [O] . Robin M.J.M. van Geel, Josep Tabernero, Elena Elez, -1

机译：Encorafenib（LGX818）和西妥昔单抗联合或不联合Alpelisib治疗转移性BRAF突变型结直肠癌的1b期剂量递增研究
5. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma [O] . Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, 2017

机译：转移性BRAF突变型黑素瘤中BRAF抑制剂Encorafenib（LGX818）的I期剂量递增和扩增研究

Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

著录项

相似文献

相关主题

期刊订阅